Search results for "proliferative disorders"

showing 10 items of 64 documents

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

2018

Blastic Plasmacytoid Dendritic Cell Neoplasm is a rare and aggressive hematological malignancy currently lacking an effective therapy. To possibly identify genetic alterations useful for a new treatment design, we analyzed by whole-exome sequencing fourteen Blastic Plasmacytoid Dendritic Cell Neoplasm patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program as the most significantly undermined (P<.0001). In particular, twenty-five epigenetic-modifiers were found mutated (e.g., ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1 was the most frequently affected (28.6% of cases). To evaluate the impact of …

Acute Myeloid LeukemiaBlastic plasmacytoid dendritic cell neoplasm epigenetic mutationsSkin NeoplasmsAzacitidineDecitabinePlasmacytoid dendritic cellGene mutationBiologyDecitabineBPDCNArticleEpigenesis Genetic03 medical and health sciences0302 clinical medicineHistone methylation5’-Azacytidine; Acute Myeloid Leukemia; BPDCN; Decitabine; WESmedicineHumansEpigeneticsExome sequencingRegulation of gene expressionMyeloproliferative DisordersDendritic CellsGenomicsHematology5 -AzacytidineMyeloid Neoplasms5’-AzacytidineCancer researchWES030215 immunologymedicine.drugHaematologica
researchProduct

Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver

1998

Studies with tumor necrosis factor p55 receptor- and interleukin-6 (IL-6)-deficient mice have shown that IL-6 is required for hepatocyte proliferation and reconstitution of the liver mass after partial hepatectomy. The biological activities of IL-6 are potentiated when this cytokine binds soluble forms of its specific receptor subunit (sIL-6R) and the resulting complex interacts with the transmembrane signaling chain gp130. We show here that double transgenic mice expressing high levels of both human IL-6 and sIL-6R under the control of liver-specific promoters spontaneously develop nodules of hepatocellular hyperplasia around periportal spaces and present signs of sustained hepatocyte prol…

AdenomaSTAT3 Transcription FactorAdenomail-6; liver adenomas; nodular hyperplasia; soluble il-6rMice TransgenicBiologyGeneral Biochemistry Genetics and Molecular BiologyProto-Oncogene Proteins c-mycMiceMyeloproliferative Disordersil-6medicineAnimalsnodular hyperplasiaReceptorMolecular BiologyHyperplasialiver adenomasHaptoglobinsGeneral Immunology and MicrobiologyInterleukin-6General NeuroscienceLiver NeoplasmsHyperplasiaGlycoprotein 130medicine.diseaseReceptors Interleukin-6Liver regenerationLiver RegenerationDNA-Binding Proteinsmedicine.anatomical_structureGene Expression RegulationLiverSolubilityHepatocyteTrans-ActivatorsCancer researchEndothelium Vascularsoluble il-6rNodular regenerative hyperplasiaResearch ArticleThe EMBO Journal
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

2020

Aims Renal changes in patients with myeloproliferative neoplasms (MPNs) or myelodysplastic syndrome (MDS)/MPNs have been addressed by few, respectively no, reports. The aim of this study was to focus on a systematic evaluation of renal biopsies in patients with MPNs or MDS/MPNs. Methods and results The cohort comprised 29 patients (23 men) aged 67 ± 11 years (mean ± standard deviation), diagnosed with chronic myeloid leukaemia (n = 5), polycythaemia vera (n = 9), primary myelofibrosis (n = 5), essential thrombocythaemia (n = 2), or chronic myelomonocytic leukaemia (n = 4), as well as MPNs or MDS/MPNs not otherwise specified (n = 4). Patients manifested with proteinuria (93%), partially in t…

AdultMale0301 basic medicinemedicine.medical_specialtyPolycythaemiaHistologyThrombotic microangiopathy610 MedizinRenal functionMesangial hypercellularityGastroenterologyPathology and Forensic MedicineNephropathyCohort Studies03 medical and health sciencesGlomerulonephritis0302 clinical medicineRisk FactorsNeoplasmshemic and lymphatic diseasesInternal medicine610 Medical sciencesmedicineHumansddc:610MyelofibrosisAgedAged 80 and overMyeloproliferative DisordersProteinuriaThrombotic Microangiopathiesbusiness.industryGlomerulonephritisGeneral MedicineMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative Diseases030104 developmental biologyMyelodysplastic Syndromes030220 oncology & carcinogenesisFemaleKidney Diseasesmedicine.symptombusiness
researchProduct

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: first results from a patient survey by the German Study Group for M…

2021

AdultMaleCancer Researchmedicine.medical_specialty2019-20 coronavirus outbreakAdolescentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEGermanYoung AdultGermanySurveys and QuestionnairesInternal medicineCorrespondencemedicineHumansAgedAged 80 and overMyeloproliferative DisordersSARS-CoV-2business.industryCOVID-19HematologyMiddle AgedPrognosisTelemedicinelanguage.human_languageOncologylanguageFemalePatient surveybusinessFollow-Up StudiesLeukemia Research
researchProduct

Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.

2009

Aims: Essential thrombocythaemia (ET) and primary myelofibrosis (PMF) share some clinical and pathological features, but show different biological behaviour and prognosis. The latest contributions to understanding the nature of these disorders have focused on bone marrow microenvironment remodelling and proliferative stress, recognising megakaryocytes (MKCs) as “key-cells”. The aim of this study was to investigate the apoptotic profile of ET and PMF MKCs in order to further characterise the biology of these disorders. Methods: Bone marrow biopsy samples from 30 patients with ET, and 30 patients with PMF, were immunophenotypically studied for the expression of pro-apoptotic (Fas, Fas-L, Bax,…

AdultMalePathologymedicine.medical_specialtyBiopsyIDIOPATHIC MYELOFIBROSISApoptosisPOLYCYTHEMIA-VERASettore MED/08 - Anatomia PatologicaBiologyPathology and Forensic MedicineImmunophenotypingImmunophenotypingMegakaryocyteBone MarrowmedicineIn Situ Nick-End LabelingHumansTelomerase reverse transcriptaseMyelofibrosisMOLECULAR PERSPECTIVEAgedAged 80 and overTUNEL assayEssential thrombocythemiaC-MPLMUTATION STATUSGeneral MedicineMiddle Agedmedicine.diseasePrognosismedicine.anatomical_structureCHRONIC MYELOPROLIFERATIVE DISORDERSCELL-DEATHApoptosisPrimary MyelofibrosisRISK-FACTORSCancer researchBONE-MARROW ANGIOGENESISMYELOID METAPLASIAFemaleBone marrowMegakaryocytesThrombocythemia EssentialJournal of clinical pathology
researchProduct

AML transformation in 56 patients with Ph- MPD in two well defined populations.

2009

The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (MPD) have an inherent tendency for transformation into acute myelogenous leukaemia (AML). The long-term rate of leukaemic transformation in unselected MPD patients was studied in well-defined MPD populations in Gothenburg, Sweden and the Cote d'Or area, Burgundy, France, respectively. Over a median observation time of 15 yr, 56 subjects (7%) out of a total of 795 patients with Ph- MPD transformed to AML. The yearly incidence of AML transformation was 0.38% in polycythaemia vera (PV), 0.37% in essential thrombocythaemia (ET) and 1.09% in idiopathic myelofibrosis (IMF). The incidence of AML development was signif…

AdultMalePediatricsmedicine.medical_specialtyPolycythaemiaMyeloidIdiopathic myelofibrosisGastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL Negativehemic and lymphatic diseasesInternal medicineMedicineHumansSurvival analysisAgedAged 80 and overMyeloproliferative Disordersbusiness.industryIncidence (epidemiology)HematologyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisChronic myeloproliferative disordersLeukemiamedicine.anatomical_structureFemalebusinessMale predominanceEuropean journal of haematology
researchProduct

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

2012

International audience; BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort. METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the Côte d'Or registry and was used as a comparator to assess…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyInflammatory bowel diseaseYoung Adult03 medical and health sciences0302 clinical medicineCrohn DiseaseInterquartile range[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicineAzathioprinemedicineHumansImmunology and AllergyProspective StudiesChildeducationAgedAged 80 and overeducation.field_of_studyCrohn's diseaseThiopurine methyltransferasebiologyMercaptopurinebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidenceIncidence (epidemiology)GastroenterologyCase-control studyOdds ratioMiddle Agedmedicine.diseaseLymphoproliferative Disorders3. Good healthTreatment OutcomeCase-Control Studies030220 oncology & carcinogenesisbiology.proteinColitis UlcerativeFemale030211 gastroenterology & hepatologyFrancebusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

2013

Paraneoplastic myelitis is a rare inflammatory disorder most frequently associated with solid tumors or lymphoproliferative disorders. Patients often harbor onconeuronal antibodies and their prognosis is usually poor. Here we report a 42-year old woman with longitudinally extensive transverse myelitis and aquaporin-4 (AQP4) antibodies that led to the diagnosis of ovarian teratoma. After tumor removal and immune therapy (including corticosteroids, plasma exchange, intravenous immunoglobulins and rituximab) the patient progressively improved achieving complete recovery. Histological study of the teratoma demonstrated neural tissue containing AQP4 expressing cells and intense inflammatory infi…

AdultPathologymedicine.medical_specialtyImmunologyLymphoproliferative disordersMyelitis TransverseAutoimmune diseases Paraneoplastic syndrome Transverse myelitisTransverse myelitisDiagnosis DifferentialmedicineImmunology and AllergyHumansNeurociènciesOvarian TeratomaAutoantibodiesAquaporin 4Ovarian Neoplasmsbiologybusiness.industryParaneoplastic MyelitisTeratomamedicine.diseaseNeurologybiology.proteinRituximabFemaleSistema nerviós MalaltiesNeurology (clinical)TeratomaAntibodybusinessBiomarkersmedicine.drugInflammatory disorder
researchProduct

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

2008

The discovery of the Janus kinase 2 Val617Phe mutation has brought new insights into the development of myeloproliferative disorders; however, the pathogenesis of essential thrombocythemia and its related thrombotic complications has not been completely understood. Although the Janus kinase 2 Val617Phe mutation confirms the initially suspected clonal character of the disease, factors influencing clonal transformation and expansion in the bone marrow have not been fully detected. Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, comp…

Adultmedicine.medical_specialtyMutation MissenseOral contraceptiveEssential thrombocythemiaGastroenterologyContraceptives Oral HormonalPathogenesisMesenteric VeinsPortal thrombosisMyeloproliferative DisordersInternal medicinemedicineHumansPlateletSplanchnic CirculationJanus kinase 2Janus kinase 2biologyessential thrombocythemia Janus kinase 2 oral contraceptives portal thrombosisKinaseEssential thrombocythemiaVascular diseasebusiness.industryThrombosisHematologyGeneral Medicinemedicine.diseaseThrombocytopeniaThrombosisEndocrinologybiology.proteinFemalebusiness
researchProduct